Compositions and methods relating to proliferative diseases
Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.
1. An anti-cancer pharmaceutical composition, comprising:
N-methylabietylamine/GPR-7 {[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}(methyl)amine; and a pharmaceutically acceptable carrier.
2. The composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises liposomes.
3. A method of treating a subject having cancer, comprising: administering a therapeutically effective amount of the anti-cancer pharmaceutical composition of claim 1 to the subject.
4. The method of claim 3 , wherein the anti-cancer pharmaceutical composition is effective to preferentially inhibit the PI3K, MAPK and STAT pathways in a cancer cell compared to a non-cancer cell.
5. The method of claim 3 , wherein the subject is human.
6. The method of claim 3 , further comprising administration of an adjunct anti-cancer treatment.